<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39325588</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2641-7650</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Kidney360</Title><ISOAbbreviation>Kidney360</ISOAbbreviation></Journal><ArticleTitle>The COVID-19 Vaccination and IgA Nephropathy: Further Cause for Reassurance.</ArticleTitle><Pagination><StartPage>1229</StartPage><EndPage>1231</EndPage><MedlinePgn>1229-1231</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.34067/KID.0000000000000530</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selvaskandan</LastName><ForeName>Haresh</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2874-7005</Identifier><AffiliationInfo><Affiliation>John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom and Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barratt</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9063-7229</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney360</MedlineTA><NlmUniqueID>101766381</NlmUniqueID><ISSNLinking>2641-7650</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.34067/KID.0000000000000498</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005922" MajorTopicYN="Y">Glomerulonephritis, IGA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/KN9/A613.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325588</ArticleId><ArticleId IdType="pmc">PMC11441805</ArticleId><ArticleId IdType="doi">10.34067/KID.0000000000000530</ArticleId><ArticleId IdType="pii">02200512-202409000-00001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Demetriou CA Achilleos S Quattrocchi A, et al. . Impact of the COVID-19 pandemic on total, sex- and age-specific all-cause mortality in 20 countries worldwide during 2020: results from the C-MOR project. Int J Epidemiol. 2023;52(3):664–676. doi:10.1093/ije/dyac170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac170</ArticleId><ArticleId IdType="pmc">PMC9452146</ArticleId><ArticleId IdType="pubmed">36029524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WE Woo Park S Weinberger DM, et al. . Direct and indirect mortality impacts of the COVID-19 pandemic in the United States, March 1, 2020 to January 1, 2022. Elife. 2023;12:e77562. doi:10.7554/eLife.77562</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.77562</ArticleId><ArticleId IdType="pmc">PMC9946455</ArticleId><ArticleId IdType="pubmed">36811598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed I Nauman A Paul P, et al. . The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccines Immunother. 2022;18(1):2027160. doi:10.1080/21645515.2022.2027160</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2027160</ArticleId><ArticleId IdType="pmc">PMC8862168</ArticleId><ArticleId IdType="pubmed">35113777</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gregorio C, Calcaterra G, Kounis NG, Bassareo PP, Mehta JL. Cerebral venous thrombosis after COVID-19 vaccines: do we know the mechanism? Lancet Reg Health Eur. 2022;16:100387. doi:10.1016/j.lanepe.2022.100387</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100387</ArticleId><ArticleId IdType="pmc">PMC9008443</ArticleId><ArticleId IdType="pubmed">35437521</ArticleId></ArticleIdList></Reference><Reference><Citation>Buoninfante A, Andeweg A, Genov G, Cavaleri M. Myocarditis associated with COVID-19 vaccination. NPJ Vaccines. 2024;9(1):122. doi:10.1038/s41541-024-00893-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00893-1</ArticleId><ArticleId IdType="pmc">PMC11213864</ArticleId><ArticleId IdType="pubmed">38942751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonishi H Katada R Kofune K, et al. . New-onset immunoglobulin-A nephropathy post severe acute respiratory syndrome-coronavirus-2 infection indicates rapidly progressive glomerulonephritis. Nephrology (Carlton). 2022;27(6):542–543. doi:10.1111/nep.14003</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.14003</ArticleId><ArticleId IdType="pmc">PMC9011634</ArticleId><ArticleId IdType="pubmed">34811854</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki R Nihei Y Matsuzaki K, et al. . Gross hematuria after the COVID-19 mRNA vaccination: nationwide multicenter prospective cohort study in Japan. Kidney360. 2024;5(9):1322–1332. doi:10.34067/KID.0000000000000498</Citation><ArticleIdList><ArticleId IdType="doi">10.34067/KID.0000000000000498</ArticleId><ArticleId IdType="pmc">PMC11441798</ArticleId><ArticleId IdType="pubmed">38976886</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaskandan H, Barratt J, Cheung CK. Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link. Int J Immunogenet. 2022;49(1):8–21. doi:10.1111/iji.12561</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iji.12561</ArticleId><ArticleId IdType="pubmed">34821031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Huang Y, Xu G. New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination. QJM. 2023;116(3):181–195. doi:10.1093/qjmed/hcac287</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcac287</ArticleId><ArticleId IdType="pubmed">36592052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CS Glenn DA Helmuth M, et al. . Association of COVID-19 versus COVID-19 vaccination with kidney function and disease activity in primary glomerular disease: a report of the cure glomerulonephropathy study. Am J Kidney Dis. 2024;83(1):37–46. doi:10.1053/j.ajkd.2023.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2023.07.008</ArticleId><ArticleId IdType="pmc">PMC10841160</ArticleId><ArticleId IdType="pubmed">37657635</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>